Europe — EMA
Glucose Bioluz
Glucose Bioluz is an IV glucose solution for hypoglycemia, parenteral nutrition, and fluid replacement, available by prescription in the EU.
Request sourcing
What is Glucose?
Glucose Bioluz is an intravenous solution containing glucose as the active ingredient. It is supplied in a sterile liquid form for parenteral administration, marketed in the European Union and available by prescription. The product provides a carbohydrate source for energy and fluid replacement when given intravenously. Each vial is designed for aseptic use and may be combined with other compatible IV fluids as part of a comprehensive nutrition regimen.
What is Glucose used for?
Glucose Bioluz is indicated for several clinical situations where rapid carbohydrate delivery and fluid balance are required.
- Treatment of hypoglycemia when oral glucose is not feasible. - Provision of calories in patients receiving parenteral nutrition. - Fluid and electrolyte replacement in dehydration or postoperative care. - Support during surgery or critical illness when enteral feeding is contraindicated. - Dilution and compatibility with other intravenous medications as directed by clinical protocols.
What are the side effects of Glucose?
When administered intravenously, Glucose Bioluz may be associated with a range of adverse effects, which are generally categorized by frequency and severity.
Common: - Mild hyperglycemia observed in patients with limited insulin response. - Transient nausea or vomiting related to rapid infusion rates. - Local irritation or pain at the infusion site. - Electrolyte shifts, particularly mild hyponatremia, due to dilutional effects.
Serious: - Severe hyperglycemia leading to osmotic diuresis and dehydration. - Hypersensitivity reactions, including rash, urticaria, or anaphylaxis. - Hyperosmolar hyperglycemic state in susceptible individuals. - Fluid overload causing pulmonary edema, especially in patients with cardiac dysfunction.
What precautions apply to Glucose?
Clinicians should evaluate patient-specific factors before initiating Glucose Bioluz therapy to minimize risks and ensure appropriate use.
- Assess blood glucose levels and adjust infusion rates in diabetic patients. - Monitor fluid balance and weight to avoid overload in heart or kidney disease. - Use caution in patients with known hypersensitivity to glucose solutions. - Verify compatibility with other IV drugs to prevent precipitation or instability. - Adjust electrolyte supplementation as needed due to dilutional changes. - Follow aseptic technique to reduce the risk of catheter‑related infections.
What does Glucose interact with?
Glucose Bioluz can interact with other intravenously administered agents, influencing their efficacy or safety profile.
Avoid: - Co‑administration with high‑dose insulin infusions without glucose monitoring. - Simultaneous infusion of incompatible solutions such as calcium chloride or certain antibiotics that may precipitate. - Use with dextrose‑containing parenteral nutrition formulas that could cause excessive carbohydrate load.
Use with caution: - Concurrent administration of diuretics, which may exacerbate electrolyte disturbances. - Combination with vasopressors, requiring careful monitoring of hemodynamic status. - Infusion alongside blood products, as glucose may affect cell viability and storage conditions.
